Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Combination therapy of human bone marrow–derived mesenchymal stem cells and minocycline improves neuronal function in a rat middle cerebral artery occlusion model

Fig. 3

Modified neurological severity score (mNSS). mNSS before middle cerebral artery occlusion (MCAO) and 1, 7, 14, 21, and 28 days after MCAO. The combination therapy group showed significant improvement in mNSS from day 7 compared with the control group. After 21 days, the combination group showed significant improvement in mNSS compared with the minocycline and human bone marrow–derived mesenchymal stem cell (hBM-MSC) groups. At day 28, the hBM-MSC and minocycline groups also showed significant improvement compared with the control group. *P <0.05

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512